TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03465046

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intensive therapies(CIMT/BIT): protocol 1 or protocol 2
Description: The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intensive therapies(CIMT/BIT): protocol 1 or protocol 2
Description: The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intensive therapies(CIMT/BIT): protocol 1 or protocol 2
Description: The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: intensive therapies(CIMT/BIT): protocol 1 or protocol 2
Description: The therapies applied in both protocols are intensive therapies that allow the execution of unimanual activities or bimanual activities with the affected upper limb with different doses.~the protocols were carried out at home through the family
Study: NCT00606177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: oral, 24mg(4 tablets)/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, 0mg(4tablets)/day
Study: NCT03674567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab (KEYTRUDA®)
Description: IV infusion
Study: NCT02259946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1744 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Study: NCT02152150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iron bio-fortified pearl millet
Description: Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control pearl millet
Description: Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
Study: NCT02314598

Intervention type: OTHER
Intervention: No treatment
Study: NCT02653352

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
Study: NCT02814136

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ablation
Study: NCT01810874

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transperitoneal laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extraperitoneal laparoscopic aortic lymphadenectomy
Description: Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
Study: NCT00313157

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verapamil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Study: NCT01472302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive Support Ventilation
Description: Ventilation protocol according to the patients ideal body weight

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure Controlled Ventilation
Description: Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
Study: NCT02781831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard rehab
Description: Standard hospital based rehabilitation for patients with stroke

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted gait rehabilitation
Description: An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
Study: NCT04445311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: 3 successive days ttt of ivermectin started within 48 hours of symptoms
Study: NCT04460638

Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: Saliva samples are regularly collected over a period of up to 30 consecutive days.

Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: Saliva samples are regularly collected over a period of up to 30 consecutive days.

Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: Saliva samples are regularly collected over a period of up to 30 consecutive days.

Intervention type: BIOLOGICAL
Intervention: Saliva collection
Description: Saliva samples are regularly collected over a period of up to 30 consecutive days.

Intervention type: OTHER
Intervention: Clinical assessment
Description: The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.

Intervention type: OTHER
Intervention: Clinical assessment
Description: The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
Study: NCT02062372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7 T MRI
Description: Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
Study: NCT04460638

Intervention type: OTHER
Intervention: Clinical assessment
Description: The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.

Intervention type: OTHER
Intervention: Clinical assessment
Description: The participant's clinical data will be collected regularly over a period of up to 30 consecutive days.
Study: NCT04177797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Two cycles of Toripalimab(240 mg administered as an intravenous infusion over 30 minutes per 3 weeks), concurrently paclitaxel(135 mg/m2) and carboplatin(AUC 5) administered as an intravenous infusion per 3 weeks.
Study: NCT01866696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oral implants
Description: For all cases, the following surgical and prosthetic protocol was followed.:~* Clinical examination~* Radiological examination~* Guided oral implants insertion~* Immediate Prosthetic loading~* Follow-up
Study: NCT02062372

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
Study: NCT01620593

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of placebo after castration, blinded to the patient and the study team.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin after castration, blinded to the patient and the study team.
Study: NCT00397553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Study: NCT04960462

Intervention type: PROCEDURE
Intervention: nerve root sleeve reinforcement
Description: treatment of sacral cysts in patients with sacral cysts by using nerve root sleeve reinforcement
Study: NCT04964804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: real-time ultrasound-CT fusion imaging
Description: selective lumbar nerve root block puncture under real-time ultrasound-CT fusion imaging

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound alone
Description: selective lumbar nerve root block puncture under the guidance of ultrasound alone
Study: NCT01192100

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breakfast Skipping
Description: Participants will continue to skip breakfast each morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normal Protein Breakfast Meals
Description: Participants will consume normal protein breakfast meals each morning.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein-rich Breakfast Meals
Description: Participants will consume protein-rich breakfast meals each morning.
Study: NCT00466024

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach and HEPA Air cleaners
Description: Health Coach for ETS reduction in home and 2 HEPA air cleaners

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coach and HEPA air cleaners
Description: Behavioral training and 2 HEPA air cleaners

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coach and HEPA air cleaners
Description: Behavioral training and 2 HEPA air cleaners

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Coach and HEPA air cleaners
Description: Behavioral training and 2 HEPA air cleaners
Study: NCT04614467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLBS16
Description: GCSF-mobilized autologous CD34+ cells

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isotonic solution (no CD34+ cells)
Study: NCT04739241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: premixed insulin therapy
Description: Premixed insulin treatment: 30% of the calculated dose was administered before breakfast and before lunch (biphasic insulin lispro 50% or biphasic insulin aspart 50%) and the remaining 40% of the dose before dinner (biphasic insulin lispro 25% or biphasic insulin aspart insulin 30%).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: basal bolus insulin therapy
Description: Basal-bolus insulin treatment: 50% dose in insulin glargine and 50% dose in insulin lispro or aspartic, distributed in equal parts in the 3 main meals
Study: NCT03949010

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping with space correction technique
Description: Kinesiotaping with space correction technique twice per week for two weeks along with home exercise program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping with muscle inhibition technique
Description: Kinesiotaping with muscle inhibition technique twice per week for two weeks along with home exercise program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Home exercise program which consists of stretching exercises towards neck area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercise program which consists of stretching exercises towards neck area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise program
Description: Home exercise program which consists of stretching exercises towards neck area
Study: NCT04073641

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02575989

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 1: control group
Description: Classic - current management of trauma patients by French medical teams

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2: interventional group
Description: Intervention Name : monitoring, treatment, control and prevention of hypothermia~* Continuous monitoring of body temperature~* Ambulance warming (target : 30°C)~* Patient warming with dedicated blanket~* Infusion fluid warming (and temperature control)
Study: NCT01158638

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web Mediated Step Intervention
Description: The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web Mediated Step Intervention
Description: The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
Study: NCT01520688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone, Budesonide, Beclomethasone
Description: Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone, Beclomethasone, Budesonide
Description: Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide, Fluticasone, Beclomethasone
Description: Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide, Beclomethasone, Fluticasone
Description: Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone, Fluticasone, Budesonide
Description: Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
Study: NCT01337739

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo administration (.9 normal saline sterile)
Study: NCT03225664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Given PO
Study: NCT04851340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow's Milk
Description: Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
Study: NCT01520688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beclomethasone, Budesonide, Fluticasone
Description: Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
Study: NCT00537771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg once daily oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg once daily oral dose
Study: NCT02955368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP-R212
Description: DP-R212 + C1-R212 placebo + C2-R212 placebo
Study: NCT04851340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow's Milk
Description: Participants will consume 200 mL, 300 mL, and 400 mL of 1% bovine milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Milk
Description: Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soy Milk
Description: Participants will consume 200 mL, 300 mL, and 400 mL of soy milk during the diet challenge which occurs on three consecutive days of the study. The first day of the diet challenge participants consume 200 mL, the second day 300 mL and the third day 400 mL.
Study: NCT02964182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Smoke usual brand of cigarettes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette
Description: Smoke usual brand of cigarettes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Received NRT (Electronic Cigarette - ECIG-Hi)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement
Description: Received NRT (Electronic Cigarette - ECIG-Hi)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content Cigarette
Description: Smoke very low nicotine content cigarette
Study: NCT01337739

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: Administration of Dexmedetomidine
Study: NCT02964182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content Cigarette
Description: Smoke very low nicotine content cigarette

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECIG-Hi
Description: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECIG-Hi
Description: Patients smoke ECIG-Hi for 3 weeks and then ECIG-Lo for 3 weeks.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECIG-Lo
Description: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECIG-Lo
Description: Patients smoke ECIG-Lo for 3 weeks and then ECIG-Hi for 3 weeks
Study: NCT03739853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Used in all three arms of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Used in all three arms of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Used in all three arms of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfasalazine
Description: Used in arm 2 of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfasalazine
Description: Used in arm 2 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide
Description: Used in arm 2 of study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leflunomide
Description: Used in arm 2 of study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Used in arm 3 of the study only
Study: NCT04232553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC
Study: NCT02955368

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C1-R212
Description: DP-R212 placebo + C1-R212 + C2-R212 placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C2-R212
Description: DP-R212 placebo + C1-R212 placebo + C2-R212
Study: NCT02866929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decortication
Description: Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Decortication
Description: Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontics
Description: Self-ligation brackets in upper and lower teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontics
Description: Self-ligation brackets in upper and lower teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontics
Description: Self-ligation brackets in upper and lower teeth

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontics
Description: Self-ligation brackets in upper and lower teeth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: Porcine naturally cross-linked collagen matrix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucograft
Description: Porcine naturally cross-linked collagen matrix